GB2310207A - Antiviral ureido derivatives of substituted heterocyclic compounds - Google Patents
Antiviral ureido derivatives of substituted heterocyclic compounds Download PDFInfo
- Publication number
- GB2310207A GB2310207A GB9603213A GB9603213A GB2310207A GB 2310207 A GB2310207 A GB 2310207A GB 9603213 A GB9603213 A GB 9603213A GB 9603213 A GB9603213 A GB 9603213A GB 2310207 A GB2310207 A GB 2310207A
- Authority
- GB
- United Kingdom
- Prior art keywords
- amino
- carbonyl
- methylpyrazole
- carbonylbis
- naphthalene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001420 substituted heterocyclic compounds Chemical class 0.000 title description 4
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 title description 3
- 230000000840 anti-viral effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 137
- 239000002253 acid Substances 0.000 claims description 101
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 97
- -1 {4-[ (3-amino-l-methylpyrazole-5-carbonyl) amino]-1-methylpyrrole-2-carbonyl}amino Chemical group 0.000 claims description 69
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 52
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 25
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims description 21
- INMHJULHWVWVFN-UHFFFAOYSA-N naphthalene-1,3,5-trisulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(S(=O)(=O)O)=CC(S(O)(=O)=O)=C21 INMHJULHWVWVFN-UHFFFAOYSA-N 0.000 claims description 15
- FKORGLNGEASTQE-UHFFFAOYSA-N naphthalene-1,3-disulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC(S(O)(=O)=O)=C21 FKORGLNGEASTQE-UHFFFAOYSA-N 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- HJHXKMDGTVNKKZ-UHFFFAOYSA-N (5-phosphononaphthalen-1-yl)phosphonic acid Chemical compound C1=CC=C2C(P(O)(=O)O)=CC=CC2=C1P(O)(O)=O HJHXKMDGTVNKKZ-UHFFFAOYSA-N 0.000 claims description 7
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 241000713666 Lentivirus Species 0.000 claims description 5
- 208000021601 lentivirus infection Diseases 0.000 claims description 5
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 108700012920 TNF Proteins 0.000 claims description 4
- 230000001627 detrimental effect Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 3
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 229910001868 water Inorganic materials 0.000 description 37
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 32
- 239000000243 solution Substances 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 239000007787 solid Substances 0.000 description 23
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 238000001816 cooling Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 229910006069 SO3H Inorganic materials 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 229960004132 diethyl ether Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- HYFMZOAPNQAXHU-UHFFFAOYSA-N naphthalene-1,7-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(S(=O)(=O)O)=CC=C21 HYFMZOAPNQAXHU-UHFFFAOYSA-N 0.000 description 6
- 229940086542 triethylamine Drugs 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 5
- 159000000001 potassium salts Chemical class 0.000 description 5
- INGFBMCRAIVLEI-UHFFFAOYSA-N (7-phosphononaphthalen-1-yl)phosphonic acid Chemical compound C1(=CC=CC2=CC=C(C=C12)P(O)(=O)O)P(O)(=O)O INGFBMCRAIVLEI-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 4
- 235000015497 potassium bicarbonate Nutrition 0.000 description 4
- 239000011736 potassium bicarbonate Substances 0.000 description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 4
- XJFHEUXETQFSLR-UHFFFAOYSA-N C1=CC=CC=2C(=CC(=CC1=2)P(O)(=O)O)P(O)(=O)O Chemical compound C1=CC=CC=2C(=CC(=CC1=2)P(O)(=O)O)P(O)(=O)O XJFHEUXETQFSLR-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- UPBAOYRENQEPJO-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical class CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 150000002828 nitro derivatives Chemical class 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- ZBXBOVMIODZOBQ-UHFFFAOYSA-N 1-methyl-4-nitropyrrole-2-carbonyl chloride Chemical compound CN1C=C([N+]([O-])=O)C=C1C(Cl)=O ZBXBOVMIODZOBQ-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 206010001513 AIDS related complex Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- GOPRYBNRWIBTIH-UHFFFAOYSA-M potassium;7-amino-3-sulfonaphthalene-1-sulfonate Chemical compound [K+].C1=C(S(O)(=O)=O)C=C(S([O-])(=O)=O)C2=CC(N)=CC=C21 GOPRYBNRWIBTIH-UHFFFAOYSA-M 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical group [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-dioxonaphthalene Natural products C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 description 1
- WEIADJNWJBUGAN-UHFFFAOYSA-N 1,5-bis(diethoxyphosphoryl)-3-nitronaphthalene Chemical compound C1=C([N+]([O-])=O)C=C2C(P(=O)(OCC)OCC)=CC=CC2=C1P(=O)(OCC)OCC WEIADJNWJBUGAN-UHFFFAOYSA-N 0.000 description 1
- YFSRROWPPOTEKH-UHFFFAOYSA-N 1,5-bis(diethoxyphosphoryl)naphthalene Chemical compound C1=CC=C2C(P(=O)(OCC)OCC)=CC=CC2=C1P(=O)(OCC)OCC YFSRROWPPOTEKH-UHFFFAOYSA-N 0.000 description 1
- BOKGTLAJQHTOKE-UHFFFAOYSA-N 1,5-dihydroxynaphthalene Chemical compound C1=CC=C2C(O)=CC=CC2=C1O BOKGTLAJQHTOKE-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- PDQGEKGUTOTUNV-TZSSRYMLSA-N 4'-deoxy-4'-iododoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](I)[C@H](C)O1 PDQGEKGUTOTUNV-TZSSRYMLSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- BVUGRJNJLAOFIZ-UHFFFAOYSA-N 4,8-bis(diethoxyphosphoryl)naphthalen-2-amine Chemical compound C1=C(N)C=C2C(P(=O)(OCC)OCC)=CC=CC2=C1P(=O)(OCC)OCC BVUGRJNJLAOFIZ-UHFFFAOYSA-N 0.000 description 1
- MUEOQEUSJMFYHV-UHFFFAOYSA-N 4-amino-1-methylpyrrole-2-carboxylic acid Chemical compound CN1C=C(N)C=C1C(O)=O MUEOQEUSJMFYHV-UHFFFAOYSA-N 0.000 description 1
- YUOXUDCQLRCIIX-UHFFFAOYSA-N 4-amino-n-[4,8-bis(diethoxyphosphoryl)naphthalen-2-yl]-1-methylpyrrole-2-carboxamide Chemical compound C1=C2C(P(=O)(OCC)OCC)=CC=CC2=C(P(=O)(OCC)OCC)C=C1NC(=O)C1=CC(N)=CN1C YUOXUDCQLRCIIX-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- UYTYLLQCQDBCDW-UHFFFAOYSA-N 5-amino-2-methylpyrazole-3-carboxylic acid Chemical compound CN1N=C(N)C=C1C(O)=O UYTYLLQCQDBCDW-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- SAIKULLUBZKPDA-UHFFFAOYSA-N Bis(2-ethylhexyl) amine Chemical compound CCCCC(CC)CNCC(CC)CCCC SAIKULLUBZKPDA-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical class [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- AXAOUZLQOYFXMQ-UHFFFAOYSA-N benzyl N-(5-carbonochloridoyl-1-methylpyrazol-3-yl)carbamate Chemical compound C(C1=CC=CC=C1)OC(=O)NC1=NN(C(=C1)C(=O)Cl)C AXAOUZLQOYFXMQ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- XXBDWLFCJWSEKW-UHFFFAOYSA-N dimethylbenzylamine Chemical compound CN(C)CC1=CC=CC=C1 XXBDWLFCJWSEKW-UHFFFAOYSA-N 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012514 monoclonal antibody product Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- YPLIFKZBNCNJJN-UHFFFAOYSA-N n,n-bis(ethylamino)ethanamine Chemical compound CCNN(CC)NCC YPLIFKZBNCNJJN-UHFFFAOYSA-N 0.000 description 1
- MQIZCWLNLGFQKE-UHFFFAOYSA-N n-[4,8-bis(diethoxyphosphoryl)naphthalen-2-yl]-1-methyl-4-nitropyrrole-2-carboxamide Chemical compound C1=C2C(P(=O)(OCC)OCC)=CC=CC2=C(P(=O)(OCC)OCC)C=C1NC(=O)C1=CC([N+]([O-])=O)=CN1C MQIZCWLNLGFQKE-UHFFFAOYSA-N 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 108010042747 stallimycin Proteins 0.000 description 1
- 229950009902 stallimycin Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- SSPQHAKUUKFFBB-UHFFFAOYSA-J tetrasodium naphthalene-1,3-disulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].C1(=CC(=CC2=CC=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-].C1(=CC(=CC2=CC=CC=C12)S(=O)(=O)[O-])S(=O)(=O)[O-] SSPQHAKUUKFFBB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4025—Esters of poly(thio)phosphonic acids
- C07F9/4028—Esters of poly(thio)phosphonic acids containing no further substituents than -PO3H2 groups in free or esterified form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4025—Esters of poly(thio)phosphonic acids
- C07F9/4037—Esters of poly(thio)phosphonic acids containing halogen or nitro(so) substituents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4025—Esters of poly(thio)phosphonic acids
- C07F9/405—Esters of poly(thio)phosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
UREIDO DERIVATIVES OF SUBSTITUTED HETEROCYCLIC COMPOUNDS
AND PROCESS FOR THEIR PREPARATION
The present invention relates to new ureido derivatives of substituted heterocyclic compounds, having biological activity, to a process for their preparation and to a pharmaceutical composition containing them.
The pyrrole derivatives of the invention may be regarded as derivatives of Distamycin A which is a known compound having the following formula
Literature referring to Distamycin A includes, for example NATURE 203, 1064 (1964).
The present invention provides ureido derivatives of substituted heterocyclic compounds having the following general formula (I)
B-CO-B (I) wherein each of the B groups, which are the same, is a group (i)
wherein m is an integer of 1 to 6; p is an integer of 1 to 3;
E is a group -CH= or -N=; each of the R groups, which are the same, is a free or esterified acid group; and the pharmaceutically acceptable salts thereof; and wherein when m is 1, then E is -N=; whereas when m is an integer of 2 to 6, then at least one of the E groups is -N=.
The invention also includes within its scope all the possible isomers, stereoisomers and their mixtures and the metabolites and the metabolic precursors or bioprecursors of the compounds of formula (I).
The free, salified or esterified R groups may be on either or both the phenyl moieties of the naphthalene group.
Examples of R acidic groups, according to the present invention, for instance are those chosen from the group including sulfonic, phosphonic and carboxylic acid groups, the sulfonic and phosphonic acid groups being the preferred.
Esters of the acids of formula (I) are for instance alkyl and aryl-alkyl esters, having a branched or straight alkyl chain. Cl-C6-alkyl and phenyl-C-C6-alkyl esters, typically methyl, ethyl, propyl, iso-propyl, butyl, benzyl and phenylethyl esters are more preferred.
Examples of pharmaceutically acceptable salts are either those with inorganic bases, such as sodium, potassium, calcium and aluminum hydroxides, or with organic bases, such as lysine, arginine, N-methylglucamine, triethyl amine, triethanolamine, dibenzylamine, methylbenzylamine, di- (2-ethylhexyl) amine, piperidine, N-ethylpiperidine,
N,N-diethylaminoethylamine, N-ethylmorpholine, phenethylamine, N-benzyl-ss-phenethylamine, N-benzyl-N , N- dimethylamine and the other acceptable organic amines.
Sodium and potassium salts are preferred.
The substituted naphthyl groups are typically 1- or 2aminonaphthyl groups.
When the naphthyl groups are substituted by three free, esterified or salified acid groups, as defined above, the acid substituents are preferably in the 4,6,8-, 3,6,8-, 3,7,8- positions.
When they are substituted by two free, esterified or salified acid groups, the acid substituents are preferably in the 1,5-, 3,6-, 3,8-, 4,6-, 4,7-, 4,8-, 5,7- or 6,8- positions.
When they are substituted by one free, esterified or salified acid group, the acid substituent is preferably in the 1-, 2-, 3-, 4-, 5-, 6-, 7- or 8- position, of course is not linked to the amino position.
The substituted heterocyclic rings, containing substituent E, are typically amino - carbonyl disubstituted. The amino and carbonyl groups may be independently linked to any of the 2 to 5 carbon positions of the heterocyclic ring; of course,such groups are not both linked to the same carbon position. When E is -CH= , the disubstituted heterocycles are typically N methyl-2 , 4-disubstituted pyrroles, preferably 1methylpyrrole-4-amino-2-carbonyl and l-methylpyrrole-2amino-4-carbonyl derivatives. When E is -N=, the disubstituted heterocycles are typically N-methyl-3,5disubstituted pyrazoles, preferably l-methylpyrazole-3amino-5-carbonyl and l-methylpyrazole-5-amino-3-carbonyl derivatives.
As already said, the invention includes within its scope also the esters and the pharmaceutically acceptable salts of the acids of formula (I).
Only one or both of the two acidic functions of each phosphono (HO)2PO-group are salified and/or esterified.
In the salts of the invention preferably only one of the two acidic functions of each phosphono group is in a salified form, whereas in the esters of the invention both the two acidic functions of each phosphono group are preferably in an esterified form.
As stated above, the present invention also includes within its scope pharmaceutically acceptable bio precursors (otherwise known as pro-drugs) of the compounds of formula (I), i.e. compounds which have a different formula to formula (I) above but which nevertheless upon administration to a human being are converted directly or indirectly in vivo into a compound of formula (I).
Preferred compounds of the invention are the compounds of formula (I), wherein each of the B groups, which are the same, is a group (i) as defined above, wherein m is 2 or 3; one of the E groups is -N=, the others being -N= or
CH=; p is 2 or 3; and each of the R groups, which are the same, is a free or esterified phosphonic or sulfonic acid group; and the pharmaceutically acceptable salts thereof.
Examples of preferred compounds of the invention are:
Carbonylbis-2-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino] -1-methylpyrazole-5-carbonyl }amino) naphthalene- 6,8-disulfonic acid; Carbonylbis-2- ( {4-[ (3-amino-l-methylpyrazole-5-carbonyl) amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
6,8-disulfonic acid;
Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl)
amino]-l-methylpyrazole-5-carbonyl}amino)naphthalene
6,8-disulfonic acid; Carbonylbis-2-({5-[(5-amino-1-methylpyrazole-3-carbonyl)
amino] -1-methylpyrazole-3-carbonyl}amino) naphthalene- 6,8-disulfonic acid;
Carbonylbis-2-({4-[(5-amino-1-methylpyrazole-3-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
6,8-disulfonic acid;
Carbonylbis-2-({5-[(4-amino-1-methylpyrrole-2-carbonyl) amino]-1-methylpyrazole-3-carbonyl}axnino) naphthaiene- 6,8-disulfonic acid;
Carbonylbis-1-({3-[(3-amino-1-methylpyrazo]e-5-carbonyl) amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene- 4, 6,8-trisulfonic acid;
Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene 4, 6, 8-trisulfonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl)
amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene
4,6,8-trisulfonic acid;
Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene- 4, 6-disulfonic acid;
Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene- 4,6-disulfonic acid; Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl)
amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene- 4,6-disulfonic acid;
Carbonylbis-2-({3-[(3-amino-l-methylpyrazole-5-carbonyl) amino] -1-methylpyrazole-5-carbonyl} amino) naphthalene- 4,6,8-trisulfonic acid; Carbonylbis-2-({4-t(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene- 4,6,8-trisulfonic acid;
Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino] -1-methylpyrazole-5-carbonyl}amino) naphthalene- 4,6,8-trisulfonic acid;
Carbonylbis-2-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene- 1,5-disulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
1,5-disulfonic acid; Carbonylbis-2- ({3- (4-amino-l-methylpyrrole-2-carbonyl) amino]-l-methylpyrazole-5-carbonyl}amino)naphthalene
1,5-disulfonic acid;
Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-l-methylpyrazole-5-carbonyl}amino)naphthalene-8
sulfonic acid; Carbonylbis-1- ( {4-[ (3-amino-l-methylpyrazole-5-carbonyl)
amino]-l-methylpyrrole-2-carbonyl}amino) naphthalene-8- sulfonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl)
amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene-8
sulfonic acid;
Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl)
amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene-4
sulfonic acid;
Carbonylbis-1-({4-[{3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene-4
sulfonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino] -l-methylpyrazole-5-carbonyl )amino) naphthalene-4 - sulfonic acid;
Carborylbis-2-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-1-methylpyrazole-5-carbonyl}amino)-5-hydroxy naphthalene-7-sulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)-5-hydroxy
naphthalene-7-sulfonic acid;
Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino) -l-methylpyrazole-5-carbonyl}amino) -5-hydroxy naphthalene-7-sulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene- 4,6-disulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
5,7-disulfonic acid; Carbonylbis-1-{[4-({4-[(3-amino-1-methylpyrazole-5-
carbonyl) -amino] -1-methylpyrrole-2-carbonyl}amino) -1-
methyl-pyrrole-2-carbonyl]amino}naphthalene-4,6- disulfonic acid;
Carbonylbis-2-{[4-({4-[(3-amino-1-methylpyrazole-5
carbonyl)-amino]-1-methylpyrrole-2-carbonyl}amino)-1
methyl-pyrrole-2-carbonyl]amino}naphthalene-4,6,8
trisulfonic acid;
Carbonylbis-2-{[3-({4-[(4-amino-1-methylpyrrole-2 carbonyl)-amino]-l-methylpyrrole-2-carbonyl}amino)-l- methyl-pyrazole-5-carbonyl]amino}naphthalene-4,6,8
trisulfonic acid;
Carbonylbis-2-({3-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-l-methylpyrazole-5-carbonyl}amino)naphthalene
4,8-diphosphonic acid; Carbonylbis-2- ({4-( (3-amino-1-methylpyrazole-5-carbonyl)
amino) -1-methylpyrrole-2-carbonyl}amino) naphthalene- 4, 8-diphosphonic acid;
Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl)
amino]-l-methylpyrazole-5-carbonyl}amino)naphthalene
4,8-diphosphonic acid; Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-l-methylpyrazole-5-carbonyl}amino)naphthalene
4,6-diphosphonic acid;
Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
4,6-diphosphonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene- 4,6-diphosphonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene- 6,8-diphosphonic acid;
Carbonylbis-l-({3-[(4-amino-l-methylpyrrole-2-carbonyl) amino] -1-methylpyrazole-5-carbonyl}amino) naphthalene- 5,7-diphosphonic acid;
Carbonylbis-2-{[4-({4-[(3-amino-1-methylpyrazole-5 carbonyl) amino] -1-methylpyrrole-2-carbonyl}amino) -1-
methylpyrrole-2-carbonyl]amino}naphthalene-4 , 8- diphosphonic acid;
Carbonylbis-1-{[4-({4-[(3-amino-1-methylpyrazole-5
carbonyl)amino]-1-methylpyrrole-2-carbonyl}amino)-1 methylpyrrole-2-carbonyl]amino}naphthalene-4,6- diphosphonic acid; Carbonylbis-2-{[4-({4-[ (5-amino-l-methylpyrazole-3- carbonyl)amino]-l-methylpyrrole-2-carbonyl}amino)-1 methylpyrrole-2-carbonyl]amino}naphthalene-4t8- diphosphonic acid;
Carbonylbis-1-({4-[(3-amino-l-methylpyrazole-5-carbonyl)
amino]-l-methylpyrrole-2-carbonyl}amino)naphthalene
6, 8-diphosphonic acid; Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-l-methylpyrrole-2-carbonyl}amino)naphthalene
5, 7-diphosphonic acid; and the Cl-C6-alkyl and phenyl-C-C6-alkyl esters and the pharmaceutically acceptable salts thereof.
Particularly preferred are the methyl, ethyl and benzyl esters and the sodium and potassium salts of the said examples of specific compounds of the invention.
The compounds of formula (I) and the pharmaceutically acceptable salts thereof are hereafter also referred to as "the compounds of the invention" or as "the active agents of the invention".
The compounds of the invention, and the salts thereof can be prepared by a process comprising reacting a compound of formula (II) or (III), respectively
wherein m, p, E and R are as defined above, or a salt thereof, with a compound of formula (IV)
wherein each of the X groups, which may be the same or different, is a good leaving group, E is as defined above, q is 0 to 6 and wherein, when a compound of formula (IV) is reacted with a compound of formula (II), then q is 0 to 5 in such a way that [q+(m-l)] is 0 to 5, whereas when a compound of formula (IV) is reacted with a compound of formula (III), then q is an integer of 1 to 6 and, if desired, converting a compound of formula (I) into another compound of formula (I), and/or, if desired, salifying a compound of formula (I) thus obtained, and/or, if desired, obtaining a free acid of formula (I) from an ester or a salt thereof, and/or, if desired, esterifying an acid of formula (I).
A salt of a compound of formula (II) or (III) may be a salt with organic or inorganic bases, for example those mentioned above as to the pharmaceutically acceptable salts of the invention, the sodium and potassium salts being the preferred.
Compounds of formula (IV) are known products or may be easily obtained according to known methods from known products.
Preferred examples of good leaving groups, according to the meaning of X, are halogen atoms, in particular chlorine, or other easily displaceable groups such as, imidazolyl, triazolyl, p-nitrophenoxy or trichlorophenoxy.
The reaction of a compound of formula (II) or (III), or a salt thereof, with a compound of formula (IV) is an analogy process and can be carried out according to well known methods; for example according to the conditions described in organic chemistry for this kind of reaction, i.e. for synthesis of urea derivatives. Preferably the reaction may be carried out at a molar ratio of compound (II) or (III), or a salt thereof : compound (IV) from about 1 : 0.5 to about 1 : 4. According to a preferred embodiment of the invention, when the compound of formula (IV) is phosgene, bis(trichloromethyl)carbonate or trichloromethyl chloroformate can be used as a phosgene source, according to known methods.
The reaction is preferably performed in an organic solvent, such as dichloromethane, dichloroethane, chloroform, toluene, or dimethylsulphoxyde, dimethyl formamide, dimethylacetamide, hexamethylphosphoramide , or their aqueous mixtures, or in water/dioxane, water/ toluene or water/dichloromethane mixtures, in the presence of either an organic base such as triethylamine, diisopropylethylamine or pyridine or an inorganic base such as sodium bicarbonate or sodium acetate or a convenient buffer as known in the art. The reaction temperature may vary from about -100C to about 150C and the reaction time from about 1 to 24 hours.
The compounds of formula (I) prepared according to the above described procedures may be purified by conventional methods such as by silica gel, alumina or reversed phase column chromatography, and/or by recrystallization from organic solvents such as lower aliphatic alcohols or dimethylformamide or their mixtures or in water containing mixtures.
Analogously, esterification or salification of an acid of formula (I) can be carried out by known methods in the art.
The compounds of formula (II), and the salts thereof, are new compounds and are a further object of the present invention.
The compounds of formula (II), and the salt thereof, can be obtained according to analogy processes.
For instance, a compound of formula (II) can be obtained by deprotection or reduction of a compound of formula (V) or a salt thereof
wherein
Z is a protected amino group according to the chemistry of peptides, or a group generating an amine function by reduction, such as -NHCOOCH2Ph or NO2, m, p, E and R are as defined above; by methods well known in the art.
The compounds of formula (V) can be obtained by reacting an amine of formula (III) as defined above, or a salt thereof as defined above, with a compound of formula (VI)
wherein m, E, Z and X are as defined above.
Also the reaction of an amine of formula (III), or a salt thereof, with a compound of formula (VI) is a well known process.
Alternatively, a compound of formula (V) wherein m is 2, 3, 4, 5 or 6 may be obtained by a multi-step-process comprising reacting a compound of formula (VII)
wherein
E, Z and X are as defined above, with an amine of formula (III),or a salt thereof, as defined above. The reaction, which may be carried out according to known methods, provides a compound of formula (VIII) or a salt thereof
wherein
Z, E, R and p are as defined above.
A compound of formula (VIII), or a salt thereof, can be deprotected or reduced according to known methods to provide a compound of formula (IX), or a salt thereof
wherein E, p and R are as defined above, which in its turn is reacted with a compound of formula (VII), as defined above, thus obtaining a compound of formula (V), as defined above, wherein m is 2. If a compound of formula (V), wherein m is 3, 4, 5 or 6 is desired, further deprotection or reduction and acylation steps are required.
The compounds of formula (VI) are known compounds or may be obtained, for example, according to Heterocycles, vol. 27, No. 8, p. 1945-52 (1988).
The compounds of formula (VII) are known products or may be easily obtained according to known methods.
The amines of formula (III) as defined above and the salts thereof, wherein R is a carboxylic or a sulfonic acid groups are known compounds, for instance the sulfonic ones are described in PCT/EP91/00014. Those wherein R is a phosphonic acid group are new compounds and are a further object of this invention.
An amine of formula (III) wherein R is a free, salified or esterified phosphonic acid group, now indicated as R', and p is as defined above, or a salt thereof, can be obtained by reducing a nitro derivative of formula (X) or a salt thereof
wherein R' and p are as defined above, according to known methods.
A nitro derivative of formula (X) can be obtained by nitration of a suitable free, esterified or salified mono-, di- or tri-phosphonic naphthalenic acid. In its turn said free, esterified or salified acid can be obtained by reacting a naphthalene compound substituted by 1, 2 or 3 trifluoromethanesulfonate group(s) or halogen atom(s), e.g. bromine or iodine, respectively with a di-C1-C6-alkyl-, di-aryl-, e.g. di-phenyl- or diaryl-alkyl, e.g. di-phenyl -C-C6-alkyl phosphite, in the presence of an organic basic agent, e.g. triethylamine, diisopropylamine or pyridine, and a suitable catalytic agent, e.g. tetrakis(triphenylphosphine) palladium(O), platinum(0) or nickel(0), at a temperature ranging from about OOC to about 150"C.
A naphthalene compound substituted by 1, 2 or 3 trifluoromethanesulfonate groups can be obtained by reacting a mono-, di- or tri-hydroxy substituted naphthalene compound, respectively, with a reactive trifluoromethanesulfolic acid derivative, e.g. the chloride or anhydride, in the presence of an organic basic agent, e.g. pyridine or triethylamine, if the case in an organic inert solvent, e.g. dichloromethane, diethylether or toluene.
Alternatively a compound substituted by one, two or three trifluoromethanesulfonate or halogen group(s) can be nitrated with known methods and the nitro derivative thus obtained subjected to reaction with di-alkyl(aryl) phosphite as above reported, to obtain the formula (X) derivative.
A salt of a compound of formula (II), (III), (V), (VIII), (IX) or (X) may be a salt with organic or inorganic bases, for example those mentioned above as to the compounds of formula (I), the sodium and potassium salts being the preferred ones.
PHARMACOLOGY
The new compounds of formula (I), and the pharmaceutically acceptable salts thereof, according to the present invention, are angiogenesis inhibitors, as shown, e.g., by the fact that they have been found to be active in the chorioallantoic membrane test, according to the
Folkman's method [Nature, 297, 307 (1982)]. Therefore the compounds of the present invention are useful in treating several pathological conditions in mammals, including humans, where the growth of new blood vessels is detrimental, for example, in chronic inflammation, diabetic retinopathy, psoriasis, rheumatoid arthritis and tumor growth. In particular, in the cancer therapy the compounds of the invention can be administered alone or in association with antitumor agents such as doxorubicin, etoposide, fluorouracil, melphalan, 4'-iododoxorubicin, methoxy-morpholino-doxorubicin, cyclophosphamide, bleomycin, vinblastin or mitomycin.
The compounds of the present invention have also been found to be endowed with TNFa-neutralizing activity and therefore they can be employed in humans for prophylactic and/or therapeutic use in any disease state in which TNFa is known to play a detrimental role. Typically such disease states are cachexia, septic shock, graft-versushost disease, multiple sclerosis, anti-CD3 monoclonal antibody-induced cytokine-release syndrome, AIDS, cerebral malaria, rheumatoid arthritis. The TNFainhibiting activity of the compounds according to the present invention is proven, for instance, by the fact that they are active in inhibiting the cytotoxicity activity of human TNFa on untreated mouse LM cells.
Accordingly, the new compounds of the invention can be used as angiogenesis inhibitors and/or as TNFaneutralizing activity agents. The compounds of the invention can thus be used in the preparation of a medicament for use in the treatment of angiogenesis and/or for prophylactic and/or therapeutic use in a disease state in which TNFa plays a detrimental role. In these therapeutical applications the compounds of the invention can be administered by the usual routes, for example, parenterally, e.g. by intravenous injection or infusion, intramuscularly, subcutaneously, topically or orally. The dosage depends on the age, weight and conditions of the patient and on the administration route. For example, a suitable dosage for administration to adult humans may range from about 0.5 to about 300 mg pro dose 1-4 times a day.
Moreover, the compounds of the present invention have been found to act directly as anti-lentivirus agents, in particular against Human Immunodeficiency Virus (HIV).
For instance, the representative compounds of the invention Carbonylbis-2- ( {4-[ (3-amino-l-methylpyrazole-5- carbonyl) amino] -l-methylpyrrole-2-carbonyl}amino) naphthalene-6,8 disulfonic acid, Carbonylbis-2-({3-[ (3- amino-1-methyl-pyrazole-5-carbonyl)amino]-1-methyl pyrazole-5-carbonyl}amino) naphthalene-6,8-disulfonic acid, Carbonylbis-2-({3-[ (4-amino-1-methylpyrrole-2- carbonyl)amino]-l-methylpyrazole-5-carbonyl}amino) naphthalene-6,8-disuifonic acid and Carbonylbis-2-C[4- ({4-[ (3-amino-1-methylpyrazole-5-carbonyl)amino]-1- methylpyrrole-2-carbonyl}amino)-l-methylpyrrole-2 carbonyl]aminoXnaphthalene-4,8-diphosphonic acid have been found to be active in the biological test described in J. Natl. Cancer Inst. 81, 557-586 (1989). A human patient suffering from lentivirus infection can thus be treated by a method comprising administering thereto an effective amount of a compound of the invention. In this way, the compounds of the invention can be used to treat an infection attributable to a lentivirus, in particular a human immunodeficiency virus, especially HIV-1 or
HIV-2.
The compounds of the invention can also be used in the preparation of a medicament for use in the treatment of a human patient suffering from lentivirus infection. The said medicament may be for use as an anti-lentivirus agent, for example an anti-HIV-1 or -HIV-2 agent. The said medicament may also be for use in ameliorating the symptoms of lentivirus-induced disease in a human patient suffering from lentivirus infection.
In particular the compounds of the invention can be used in the preparation of an agent to be used in the treatment of a human patient who is seropositive diseased, stressed or pathological as a result of infection with a lentivirus, in particular HIV, or who is suffering from induced disease, e.g., lymphoadenopathy syndrome (LS), AIDS-related complex (ARC), AIDS or
Kaposi's sarcoma. The condition of a human patient can thus be ameliorated or improved.
In these therapeutical applications the compounds of the invention can be administered by usual routes, for example, parenterally, e.g. by intravenous injection or infusion, intramuscularly, subcutaneously, topically or orally, intravenous injection or infusion being preferred. The dosage depends on the age, weight and condition of the patient and on the administration route.
A suitable dosage for the compounds of the invention, for example Carbonylbis-2-( {3-[ (3-amino-l-methylpyrazole-5- carbonyl) amino]-l-methylpyrazole-5-carbonyl}amino) naphthalene-6,8-disulfonic acid or a pharmaceutically acceptable salt thereof, for administration to adult humans is from about 0.4 to about 280 mg per dose 1-4 times a day.
The compounds of the invention may be used in a method of treatment of the above mentioned pathological conditions comprising both separate and substantially contemporaneous administration of a composition containing a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing different pharmaceutically active agents. The present invention therefore further provides products comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a second active agent as a combined preparation for separate, simultaneous or sequential use in treating a human patient suffering from lentivirus infection, in particular infection with HIV.
The second active agent is typically a drug that affects the pathogenesis of HIV-induced diseases.
For example, the compounds of the invention may be employed with various active agents, in particular those that affect reverse transcriptase, antimicrobial and antitumor agents or a mixture of two or more thereof.
Drugs of interest include non-nucleoside reverse transcriptase inhibitors, e.g. nevirapine; nucleoside derivatives, e.g. zidovudine and didanosine; acyclovir; ribavirin; ascorbic acid; protease inhibitors; cytokine, e.g. IL-1, IL-2, IL-3 or IL-4; growth factors; interferons, e.g. alpha- or gamma-interferon; antitumor agents, e.g. doxorubicin, daunomycin, epirubicin, 4'iododoxorubicin, methoxy-morpholino-doxorubicin, idarubicin, etoposide, fluorouracil, melphalan, cyclo phosphamide, bleomycin, vinblastin and mitomycin; immunomodulating agents, in particular immunostimulants, gamma globulin, immune globulin and monoclonal antibody products, antibiotics and antimicrobial products.
Typically, the antimicrobial agents may include a penicillin in conjunction with an aminoglycoside (e.g.
gentamycin, tobramycin).
However several well known additional agents, e.g.
cephalosporin, can be utilized.
The administration dosage of these drugs will vary, depending upon the disease status of the individual. The dosage regimen must therefore be tailored to the particular of the patient's conditions, response and associate treatments in a manner which is conventional for any therapy, and may need to be adjusted in response to changes in conditions and/or in light of other clinical conditions.
The pharmaceutical composition used in the invention may comprise a compound of formula (I) or pharmaceutically acceptable salt thereof, as the active substance, in association with one or more pharmaceutically acceptable excipients and/or carriers. The pharmaceutical compositions are usually prepa emulsifying excipients.
The solid oral forms, e.g. tablets and capsules, may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch and potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gum, gelatin, methylcellulose, carboxymethylcellulose, polyvinylpyrrolidone; disaggregating agents, e.g. a starch, alginic acid, alginates, sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, for instance, lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in a known manner, for example by means of mixing, granulating, tabletting, sugar-coating, or film-coating processes.
The following examples illustrate but do not limit the invention.
Example 1 2-{[3-(Benzyloxycarbonyl)amino-l-methylpyrazole-5 carbonyl]amino)naphthalene-6,8-disulfoni acid dipotassium salt [Compound (VIII), R= -SO3H, p= 2, Z= NHCOOCH2Ph, E= -N= ].
To a solution of 2-aminonaphthalene-6,8-disulfonic acid mono-potassium salt (85% technical, 1.03 g, 2.55 mmol), potassium bicarbonate (1.00 g, 10 mmol) in water (25 ml) and 1,4-dioxane (10 ml) a solution of 3-(benzyloxy carbonyl)amino-l-methylpyrazole-5-carboxylic acid chloride (obtained by treating the acid with SOCi2) (0.88 g, 3.0 mmol) in 1,4-dioxane (10 ml) is added dropwise, with stirring, at room temperature. The reaction mixture is diluted with water, dioxane is evaporated under reduced pressure and to the resulting aqueous solution (25 ml) potassium acetate (3 g) is added thus obtaining a microcrystalline precipitate which, after ice-cooling, is filtered, washed with ice-cooled 30% potassium acetate solution, then with ethanol and vacuum dried over phosphorus pentoxide to give the title compound (1.46 g, 90% yield).
'H NMR (DMSO-d6): 6 10.6 (br s, 1H, exchangeable with D2O); 10.1 (br s, 1H, exch. with D2O); 9.01 (d, lH);
8.27 (d, lH); 8.06 (m, lH); 7.89 (m, 2H); 7.4 (m, 5H);
7.26 (s, lH); 5.18 (s, 2H); 4.01 (s, 3H).
Example 2 2-[ (3-Amino-1-methylpyrazole-5-carbonyl)amino] naphthalene-6,8-disulfonic acid monopotassium salt [Compound (IX), R= -SO3H, p= 2, E= -N= ].
A solution of 2-([3-(benzyloxycarbonyl)amino-l-methyl pyrazole-5-carbonyl]amino}naphthalene-6, 8-disulfonic acid dipotassium salt of Example 1 (1.44 g, 2.26 mmol) in H20 (350 ml) and hydrochloric acid (2.25 ml 1 N) is hydrogenated in a PARR apparatus over 45 psi hydrogen pressure at room temperature in the presence of 5% Pd/C catalyst (500 mg). After catalyst filtration, the solution is concentrated in vacuum to 40 ml and, after ice-cooling, the precipitated solid is filtered, washed with ice-cooled water and dried in vacuum over P205 thus obtaining the title compound as a white microcrystalline solid (805 mg, 76.5% yield).
H NMR (DMSO-d6): 6 10.7(s, 1H, exch. with D2O); 8.94
(d, 1H, J=0.5 Hz); 8.28 (d, 1H, J=1.7 Hz); 8.06 (d, 1H,
J=1.4 Hz); 7.93 (m, 2H); 7.04 (s, lH); 4.06 (s, 3H).
Example 3 2-({3-[ (3-Amino-l-methylpyrazole-5-carbonyl)amino]-1- methyl pyrazole-5-carbonyl}amino)naphthalene-6,8disulfonic acid monopotassium salt [Compound (II), R= -SO3H, p= 2, m= 2, E= -N=].
To a solution of 2-[(3-amino-l-methylpyrazole-5carbonyl)amino]naphthalene-6,8-disulfonic acid monopotassium salt of Example 2 (1.02 g, 2.2 mmol) and potassium bicarbonate (1.00 g, 10 mmol) in water (40 ml) and 1,4-dioxane (15 ml), a solution of 3-(benzyloxy carbonyl) amino-l-methylpyrazole-5-carboxylic acid chloride (735 mg, 2.5 mmol) in 1,4-dioxane (10 ml) is added dropwise, with stirring, at room temperature. The reaction mixture is diluted with water, 1,4-dioxane is evaporated under reduced pressure and concentrated to a final volume of 30 ml. After ice-cooling, the resulting microcrystalline precipitate is filtered, washed with ice-cooled water and dissolved in water (500 ml). The resulting solution, after hydrochloric acid addition (2.5 ml 1N), is hydrogenated in a PARR apparatus with 5% Pd/C catalyst (350 mg) at room temperature and 45 psi hydrogen pressure. After catalyst filtration, the solution is concentrated under reduced pressure to 25 ml and icecooled. The precipitated white solid is filtered, washed with ice-cooled water, with ethanol and dried in vacuum over P205 thus obtaining the title compound as a white microcrystalline solid (665 mg, 51.5% yield).
'H NMR (DMSO-d6, 50'C): 6 11.03 (s, 1H, exch. with D2O);
10.63 (s, 1H, exch. with D2O); 8.99 (s, lH); 8.26 (d, 1H, J=1.7 Hz); 8.04 (m, 1H); 7.90 (m, 2H); 7.58 (s,
lH); 6.94 (s, lH); 4.08 (s, 3H); 4.05 (s, 3H).
Example 4 Carbonylbis-2- ({3-[ (3-amino-l-methylpyrazole-5-carbonyl) amino]-l-methylpyrazole-5-carbonyl}amino)naphthalene-6/8- disulfonic acid tetrapotassium salt [Compound (I), R= SO3H, p= 2, m= 2, E= -N= ].
To a solution of 2-({3-[ (3-amino-l-methylpyrazole-5- carbonyl)amino]-l-methylpyrazole-5-carbonyl}amino) naphthalene-6,8-disulfonic acid monopotassium salt of
Example 3 (500 mg, 0.85 mmol), potassium bicarbonate (850 mg, 8.5 mmol) in water (50 ml) and 1,4-dioxane (10 ml) a solution of bis(trichloromethyl)carbonate (250 mg, 0.85 mmol) in 1,4-dioxane (10 ml) is added dropwise, with stirring, at room temperature over 2 hrs. The reaction mixture is diluted with water, the dioxane is evaporated under reduced pressure and concentrated to a final volume of 25 ml. After ice-cooling the resulting precipitate is filtered, washed with ice-cooled water and vacuum dried over P205 thus obtaining the title compound (470 mg, 86% yield).
H NMR (DMSO-d6): 611.2 (bs, 1H, exch. with D2O); 10.7
(bs, 1H, exch. with D2O); 9.3 (bs, 1H, exch. with D2O); 8.98 (s, lH); 8.21 (d, lH, J=1.7 Hz); 8.03 (nm, lH);
7.90 (m, 2H); 7.60 (s, lH); 7.04 (s, lH); 4.08 (s, 3H);
4.03 (s, 3H).
By proceeding analogously, with the appropriate starting materials, the following sodium or potassium salts of the compounds can be obtained: Carbonylbis-2-({5-[ (5-amino-l-methylpyrazole-3- carbonyl)amino]-l-methylpyrazole-3-carbonyl}amino)
naphthalene-6, 8-disulfonic acid; Carbonylbis-2-({4-[ (5-amino-l-methylpyrazole-3- carbonyl)amino]-1-methylpyrrole-2-carbonyl}amino)
naphthalene-6, 8-disulfonic acid;
Carbonylbis-2-({5-[(4-amino-1-methylpyrrole-2
carbonyl)amino]-1-methylpyrazole-3-carbonyl}amino)
naphthalene-6, 8-disulfonic acid; Carbonylbis-l-({3-[ (3-amino-1-methylpyrazole-5- carbonyl)amino]-l-methylpyrazole-5-carbonyl}amino)
naphthalene-4,6,8-trisulfonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2 carbonyl) amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene-4,6,8-trisulfonic acid; Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino] -l-methylpyrrole-2-carbonyl } amino) naphthalene- 4,6,8-trisulfonic acid;
Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene- 4,6-disulfonic acid;
Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
4,6-disulfonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene- 4, 6-disulfonic acid;
Carbonylbis-2-({3-[(3-amino-1-methylpyrazzole-5-carbonyl) amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene- 4,6,8-trisulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene 4, 6, 8-trisulfonic acid;
Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene- 4,6,8-trisulfonic acid;
Carbonylbis-2-({3-[(3-amino-1-methylpyrazzole-5-carbonyl)
amino]-l-methylpyrazole-5-carbonyl}amino)naphthalene
1,5-disulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-l-methylpyrrole-2-carbonyl}amino)naphthalene
1,5-disulfonic acid;
Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl)
amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene
1,5-disulfonic acid; Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl)
amino] -l-methylpyrazole-5-carbonyl )amino) naphthalene-8- sulfonic acid;
Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene-8- sulfonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl)
amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene-8
sulfonic acid;
Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl)
amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene-4
sulfonic acid;
Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl) amino] -l-methylpyrrole-2-carbonyl } amino) naphthalene-4- sulfonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino] -l-methylpyrazole-5-carbonyl )amino) naphtha lene-4 - sulfonic acid;
Carbonylbis-2-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-1-methylpyrazole-5-carbonyl}amino)-5-hydroxy- naphthalene-7-sulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl) amino) -l-methylpyrrole-2-carbonyl}amino) -5-hydroxy- naphthalene-7-sulfonic acid;
Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2 carbonyl)
amino]-l-methylpyrazole-5-carbonyl}amino)-5-hydroxy
naphthalene-7-sulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
4,6-disulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-mathylpyrazola-5-carbonyl) amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene- 5,7-disulfonic acid;
Carbonylbis-1-{[4-({4-[(3-amino-1-methylpyrazole-5 carbonyl)amino]-1-methylpyrrole-2-carbonyl}amino)-1-
methylpyrrole-2-carbonyl]amino}naphthalene-4,6- disulfonic acid; Carbonylbis-2-{[4-({4-[ (3-amino-1-methylpyrazole-5- carbonyl)amino]-1-methylpyrrole-2-carbonyl}amino)-1 'methylpyrrole-2-carbonyl]amino}naphthalene-4,6,8- trisulfonic acid; and Carbonylbis-2-l[3-({4-[(4-amino-l-methylpyrrole-2-
carbonyl)amino]-1-methylpyrrole-2-carbonyl}amino)-1- methylpyrazole-5-carbonyl]amino}naphthalene-4,6,8
trisulfonic acid.
Example 5 2-[(4-amino-1-methylpyrrole-2-carbonyl)amino]naphthalene- 6, 8-disulfonic acid monopotassium salt compound (IX),
R= -SO3H, p= 2, E= -CH= ].
To a solution of 2-aminonaphthalene-6,8-disulfonic acid mono-potassium salt (technical 85%, 3.41 g, 8.5 mmol), potassium bicarbonate (2.70 g, 27 mmol) in water (80 ml) and 1,4-dioxane (40 ml) a solution of 4-nitro-l-methylpyrrole-2-carboxylic acid chloride (1.90 g, 10 mmol) (obtained by treating the acid with thionyl chloride) in 1,4-dioxane (40 ml) is added dropwise, with stirring, at room temperature. The precipitated solid is filtered, washed and dried to give the 4-nitro-derivative as dipotassium salt (4.50 g) in near quantitative yield [Compound (VIII), R= -SO3H, p= 2, Z= -NO2, E= -CH= 1 'H NMR (DMSO-d6): s 10.50 (bs, 1H, exch. with D2O); 8.98
(s, lH); 8.27 (d, 1H, J=1.7 Hz); 8.19 (d, 1H, J=1.7
Hz); 7.90 (m, 2H); 7.82 (d, 1H, J=1.9 Hz); 3.99 (s,
3H).
The above compound (2.13 g, 4 mmol) dissolved in H2O (300 ml) and hydrochloric acid (5.0 ml 1N) is hydrogenated in a PARR apparatus over 45 psi hydrogen pressure at room temperature in the presence of 5% Pd/C catalyst (500 mg).
After catalyst filtration, the solution is concentrated in vacuum to 30 ml and, after ice-cooling, the precipitated solid is filtered, washed with ice-cooled water and dried over P205 to obtain the title compound as a white microcrystalline solid (1.02 g, 55% yield).
H NMR (DMSO-d6): 6 10.25 (s, 1H, exch. with D2O) 9.75
(br, 3H, exch. with D2O); 8.91 (s, lH); 8.28 (d, lH);
8.05 (d, lH); 7.90 (nm, 2H); 7.15 (m, 2H); 3.92 (s,
3H).
Example 6 3,3'-Carbonylbis-[5-(N-imidazolecarbonyl)-3-amino-1- methyl pyrazole] compound (IV), q= 1, X= imidazolyl, E= -N= ].
To a solution of 3-amino-l-methylpyrazole-5-carboxylic acid (220 mg, 1.56 mmol), sodium bicarbonate (420 mg, 5 mmol) in water (10 ml) and 1,4-dioxane (3 ml) a solution of bis(trichloromethyl)carbonate (86 mg, 0.29 mmol) in 1,4-dioxane (2 ml) is added dropwise, with stirring and ice-cooling. The reaction mixture is brought to pH 1-2 with diluted hydrochloric acid, the precipitated solid is filtered, washed with water and dried to give 3,3'carbonylbis-3-amino-l-methylpyrazole-5-carboxylic acid
(180 mg, 75% yield).
1H NMR (DMSO-d6): 5 14-12.5 (br, lH, exch. with D2O);
9.16 (bs, 1H, exch. with D2O); 6.81 (s, 1H); 3.96 (s,
3H).
To a solution of the above acid (150 mg, 0.52 mmol) in
DMF (3 ml) N,N'-carbonyldiimidazole (195 mg, 1.2 mmol) is added portionwise, with stirring, at room temperature.
After 3 hrs, anhydrous Et2O is added and the precipitated solid is filtered, washed and dried to give the title compound (170 mg, 80% yield).
H NMR (DMSO-d6): s 9.35 (s, 1H, exch. with D2O); 8.30
(m, lH); 7.73 (t, lH); 7.17 (q, lH); 6.92 (s, lH);
3.98 (s, 3H).
Example 7 Carbonylbis-2- ( {4-[ (3-amino-l-methylpyrazole-5-carbonyl) amino)-l-methylpyrrole-2-carbonyl}amino) naphthalene-6, 8- disulfonic acid tetrasodium salt [Compound (I), R= -SO3H, p= 2, m= 2, E= -N= and -CH= ].
A mixture of 2-[(4-amino-l-methylpyrrole-2-carbonyl) amino]naphthalene-6,8-disulfonic acid monopotassium salt of Example 5 (278 mg, 0.6 mmol) and 3,3'-carbonylbis-[5 (N-imidazolecarbonyl)-3-amino-1-methylpyrazole] of
Example 6 (118 mg, 0.29 mmol) in DMF (10 ml) is warmed under N2 at 55-65'C for 3 hrs. Dimethylformamide is distilled in vacuum, ethanol added to the residue and the precipitated solid filtered and washed. The crude is dissolved in water, passed through a sulfonic acid ionexchange resin in H+ form, the acid eluate of the title compound is neutralized to pH 7.0 with NaOH solution and purified with reversed-phase liquid chromatography eluting with a gradient from H2O to H2O:methanol 80:20.
The product containing eluate is concentrated in vacuum and freeze-dried to give the yellow amorphous title compound (240 mg, 66% yield).
H NMR (DMSO-d6): 6 10.52 (s, 1H, exch. with D2O); 10.26
(s, 1H, exch. with D2O); 9.43 (bs, 1H, exch. with D2O);
8.91 (s, lH); 8.21 (d, 1H, J=1.7 Hz); 8.00 (nm, lH,);
7.86 (m, 2H); 7.34 (d, 1H, J=1.7 Hz); 7.28 (d, 1H, J=1.7 Hz); 7.06 (s, lH); 4.02 (s, 3H); 3.89 (s, 3H).
By proceeding analogously ,with the appropriate starting materials, the following compounds can be obtained either as a free or sodium salified acids:
Carbonylbis-2-({5-[(5-amino-1-methylpyrazole-3-carbonyl) amino] -1-methylpyrazole-3-carbonyl}amino) naphthalene- 6,8-disulfonic acid;
Carbonylbis-2-({4-[(5-amino-1-methylpyrazole-3-carbonyl) amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene- 6,8-disulfonic acid;
Carbonylbis-2-({5-[(4-amino-1-methylpyrrole-2-carbonyl) amino] -1-methylpyrazole-3-carbonyl}amino) naphthalene- 6,8-disulfonic acid;
Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino] -1-methylpyrazole-5-carbonyl}arnino) naphthalene- 4,6,8-trisulfonic acid; Carbonylbis-1-({3-[(4-amino-l-methylpyrrole-2-carbonyl) amino]-l-methylpyrazole-5-carbonyl}amino) naphthalene- 4,6,8-trisulfonic acid; Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene- 4,6,8-trisulfonic acid;
Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene- 4,6-disulfonic acid; Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene- 4,6-disulfonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino) -l-methylpyrazole-5-carbonyl } amino) naphthalene- 4,6-disulfonic acid;
Carbonylbis-2-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene- 4,6,8-trisulfonic.acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
4,6,8-trisulfonic acid;
Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene- 4,6,8-trisulfonic acid;
Carbonylbis-2-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino] -l-methylpyrazole-5-carbonyl } amino) naphthalene- 1, 5-disulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
1,5-disulfonic acid;
Carbonylbis-2-({3-[(4-amino-l-methylpyrrole-2-carbonyl) amino]-l-methylpyrazole-5-carbonyl}amino) naphthalene- 1,5-disulfonic acid; Carbonylbis-l-({3-[ (3-amino-l-methylpyrazole-5-carbonyl)
amino] -l-methylpyrazole-5-carbonyi}amino) naphthalene-8- sulfonic acid; Carbonylbis-1- ( {4-[ (3-amino-l-methylpyrazole-5-carbonyl)
amino]-l-methylpyrrole-2-carbonyl}amino) naphthalene-8- sulfonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl)
amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene-8
sulfonic acid; Carbonylbis-l- ({3-[ (3-amino-l-methylpyrazole-5-carbonyl)
amino] -l-methylpyrazole-5-carbonyl )amino) naphthalene-4- sulfonic acid;
Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl) amino] -l-methylpyrrole-2-carbonyl}amino) naphthalene-4- sulfonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino ] - l-methylpyrazole-5-carbonyl )amino) naphthalene-4 - sulfonic acid;
Carbonylbis-2-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-1-methylpyrazole-5-carbonyl}amino)-5-hydroxy- naphthalene-7-sulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-1-methylpyrrole-2-carbonyl}amino)-5-hydroxy- naphthalene-7-sulfonic acid;
Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino]-1-methylpyrazole-5-carbonyl}amino)-5-hydroxy- naphthalene-7-sulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5- carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
4,6-disulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5- carbonyl) amino] -l-methylpyrrole-2-carbonyl }amino) naphthalene- 5,7-disulfonic acid;
Carbonylbis-1-{[4-({4-[(3-amino-1-methylpyrazole-5
carbonyl)amino]-1-methylpyrrole-2-carbonyl}amino)-1 methylpyrrole-2-carbonyl]amino}naphthalene-4,6- disulfonic acid; Carbonylbis-2-{[4-({4-[ (3-amino-l-methylpyrazole-5- carbonyl)amino]-1-methylpyrrole-2-carbonyl}amino) -1 methylpyrrole-2-carbonyl] amino}naphthalene-4,6,8- trisulfonic acid; and
Carbonylbis-2-{[3-({4-[(4-amino-l-methylpyrrole-2 carbonyl)amino]-l-methylpyrrole-2-carbonyl}amino) -1-
methylpyrazole-5-carbonyl]amino}naphthalene-4,6,8- trisulfonic acid.
Example 8 4-4'-Carbonylbis-[2-(N-imidazolecarbonyl)-4-amino-1- methyl pyrrole] [Compound (IV), q= 1, X= imidazolyl, E= -CH= ].
To a solution of 4-amino-l-methylpyrrole-2-carboxylic acid (4.00 g, 22.6 mmol as hydrochloride), sodium bicarbonate (7.56 g, 90 mmol), in water (75 ml) and 1,4dioxane (25 ml), a solution of bis(trichloromethyl) carbonate (1.25 g, 4.2 mmol) in 1,4-dioxane (10 ml) is added dropwise, with stirring and ice-cooling. The reaction mixture is acidified to pH 1-2 with diluted hydrochloric acid, the precipitated white solid is filtered, washed with H2O and dried to give 4-4'carbonylbis-4-amino-l-methylpyrrole-2-carboxylic acid (3.29 g, 95% yield).
H NMR (DMSO-d6): 6 12.1 (br, 1H, exch. with D2O); 8.2
(s, 1H, exch. with D2O); 7.12 (d, lH); 6.62 (d, lH);
3.80 (s, 3H).
To a solution of the above acid (3.29 g, 10.75 mmol) in
N,N-dimethylformamide (50 ml) N,N'-carbonyldiimidazole (5.20 g, 32.6 mmol) is added portionwise, with stirring, at room temperature. After 4 hrs, the precipitated solid is filtered, washed with DMF, Et2Oand dried to give the title compound (3.90 g, 90t yield).
'H NMR (DMSO-d6): 6 8.75 (bs, lH); 8.25 (m, lH); 7.70
(t, lH); 7.52 (d, lH); 7.13 (m, lH); 6.80 (d, lH); 3.90
(s, 3H)
Example 9 Carbonylbis-2-({3-[ (4-amino-l-methylpyrrole-2-carbonyl) amino]-l-methylpyrazole-5-carbonyl}amino)naphthalene-6,8 disulfonic acid tetrapotassium salt [Compound (I), R=
SO3H, p= 2, m= 2, E= -CH= and -N= ].
A mixture of 2-[(3-amino-l-methylpyrazole-5-carbonyl) amino]naphthalene-68-disulfonic acid monopotassium salt of Example 2 (510 mg, 1.10 mmol) and 4-4'-carbonylbis-[2 (N-imidazolecarbonyl) -4-amino-l-methylpyrrole) of Example 8 (205 mg, 0.50 mmol) in N,N-dimethylformamide (20 ml) is warmed under N2 to 50-55'C for 4 hrs. Dimethylformamide is distilled in vacuum, ethanol is added to the residue and the precipitated solid is filtered and washed. The crude is dissolved in water, passed through a sulfonic acid ion-exchange resin in H+ form, the acid eluate of the title compound is neutralized to pH 6.5 - 7 with KOH solution and purified with reversed-phase liquid chromatography eluting with a gradient from H2O to
H2O:MeCN 80:20. The product containing eluate is concentrated in vacuum and freeze-dried to give the yellow microcrystalline title compound (300 mg, 43% yield).
1H NMR (DMSO-d6): 6 10.65, 10.44 (two multiplets, 2H,
exch. with D2O); 9.01 (nm, lH,); 8.22 (d, 1H, J=1.8
Hz); 8.2 (bs, 1H, exch. with D2O); 8.01 (nm, lH); 7.90
(m, 2H); 7.57 (s, lH); 7.14, 6.93 (two doublets, 2H,
J=1.8 Hz); 4.07 (s, 3H), 3.86 (s, 3H).
By proceeding analogously, with the appropriate starting materials, the following compounds can be obtained either as free or potassium salified compounds: Carbonylbis-2-( {5-[ (5-amino-1-methylpyrazole-3-carbonyl)
amino]-1-methylpyrazole-3-carbonyl}amino)naphthalene- 6,8-disulfonic acid; Carbonylbis-2-({4-[ (5-amino-1-methylpyrazole-3-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino) naphthalene- 6,8-disulfonic acid; Carbonylbis-2-({5-[ (4-amino-l-methylpyrrole-2-carbonyl) amino]-l-methylpyrazole-3-carbonyl}amino)naphthalene
6,8-disulfonic acid;
Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-l-methylpyrazole-5-carbonyl}amino)naphthalene
4,6,8-trisulfonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino] -1-methylpyrazole-5-carbonyl}amino) naphthalene- 4,6,8-trisulfonic acid;
Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-l-methylpyrrole-2-carbonyl}amino)naphthalene 4, 6, 8-trisulfonic acid;
Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene- 4,6-disulfonic acid;
Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
4,6-disulfonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl)
amino]-l-methylpyrazole-5-carbonyl}amino)naphthalene
4,6-disulfonic acid;
Carbonylbis-2-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene- 4,6,8-trisulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-l-methylpyrrole-2-carbonyl}amino)naphthalene
4,6,8-trisulfonic acid; Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl)
amino] -1-methylpyrazole-5-carbonyl}amino) naphthalene- 4, 6, 8-trisulfonic acid; Carbonylbis-2-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-l-methylpyrazole-5-carbonyl}amino)naphthalene
1,5-disulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
1,5-disulfonic acid;
Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino]-l-methylpyrazole-5-carbonyl}amino) naphthalene- 1,5-disulfonic acid;
Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino] -l-methylpyrazole-5-carbonyl )amino) naphthalene-8- sulfonic acid;
Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-l-methylpyrrole-2-carbonyl}amino)naphthalene-8
sulfonic acid; Carbonylbis-l- ( {3-( (4-amino-l-methylpyrrole-2-carbonyl) amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene-8
sulfonic acid;
Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino] -l-methylpyrazole-5-carbonyl )amino) naphthalene-4- sulfonic acid; Carbonylbis-l- ( {4-[ (3-amino-1-methylpyrazole-5-carbonyl)
amino] -l-methylpyrrole-2-carbonyl } amino) naphthalene-4- sulfonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino] -l-methylpyrazole-5-carbonyl }amino) naphthalene-4- sulfonic acid; Carbonylbis-2- ( {3-[ (3-amino-l-methylpyrazole-5-carbonyl) amino]-l-methylpyrazole-5-carbonyl}amino)-5-hydroxy
naphthalene-7-sulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-1-methylpyrrole-2-carbonyl}amino)-5-hydroxy- naphthalene-7-sulfonic acid;
Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl)
amino]-l-methylpyrazole-5-carbonyl}amino)-5-hydroxy
naphthalene-7-sulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
4,6-disulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
5,7-disulfonic acid;
Carbonylbis-1-{[4-({4-[(3-amino-1-methylpyrazole-5
carbonyl)amino]-1-methylpyrrole-2-carbonyl}amino)-1
methylpyrrole-2-carbonyl]amino}n
disulfonic acid;
Carbonylbis-2-{[4-({4-[(3-amino-1-methylpyrazole-5 carbonyl)amino]-l-methylpyrrole-2-carbonyl}amino)-l-
methylpyrrole-2-carbonyl]amino}naphthalene-4v6t8- trisulfonic acid; and Carbonylbis-2-{[3-({4-[ (4-amino-1-methylpyrrole-2- carbonyl)amino]-1-methylpyrrole-2-carbonyl}amino)-1 methylpyrazole-5-carbonyl]amino}naphthalene-4#6r8- trisulfonic acid.
Example 10
Naphthalene-1,5-diphosphonic acid tetraethyl ester.
Naphthalene-1,5-ditrifluoromethanesulfonate (16.46 g, 40 mmol) (prepared by treating 1, 5-dihydroxynaphthalene with trifluoromethanesulfonic anhydride in pyridine, m.p. 112 113-C), diethyl phosphite (13.81 g, 100 mmol), dry N,Ndiisopropylethylamine (15.51 g, 120 mmol), tetrakis (triphenylphosphine)palladium(0) (1.00 g, 0.86 mmol) in 50 ml N,N-dimethylformamide are heated to 95-100 C for 3 hrs. After cooling, the reaction mixture is poured into
H2O and extracted with ethyl acetate. The organic extract is washed with H2O, diluted acid, NaHCO3 solution, H2O, dried (Na2SO4), concentrated under reduced pressure to 50 ml and diluted with 25 ml diethyl ether. After icecooling, the separated crystalline solid is filtered, washed with diethyl ether and dried to yield the title compound (12.23 g, m.p. 169-171-C, 76.4% yield).
Cl8H2606P2 found (calc.) % : C 53.74 (54.00), H 6.53
(6.55), EI MS : 400 (M)+.
'H NMR (CDC13): 6 8.82 (dd, 2H, J=8.7 Hz, J=1.2 Hz);
8.30 (ddd, 2H, J=1.2 Hz, J=6.9 Hz, J=15.6 Hz); 7.65
(ddd, 2H, J=3.9 Hz, J=6.9 Hz, J=8.7 Hz); 3.9-4.5 (m,
8H); 1.32 (t, 12H, J=7.2 Hz).
Example 11 3-Nitronaphthalene-1,5-diphosphonic acid tetraethyl ester. [Compound (X), R'= -PO(OEt)2, p= 2 ].
Naphthalene-l,5-diphosphonic acid tetraethyl ester of
Example 10 (10.21 g, 25.5 mmol) is dissolved portionwise in ice-cooled 96% H2SO4 and sulphonitric mixture (2.5 ml 90% HNO3 in 7.5 ml 96% H2SO4) is added dropwise in 15 min.
After 30 min in ice-cooling, the reaction mixture is poured into ice-water mixture and extracted with ethyl acetate. The organic extract is washed with H2O, NaHCO3 solution, dried, concentrated under reduced pressure to 20 ml and diluted with 30 ml cyclohexane. After icecooling, the separated crystalline solid is filtered, washed and dried to yield the title compound (8.48 g, m.p. 117-118.5-C, 74.7% yield).
CISH25N08P2 found (calculated) % : C 48.31 (48.54), H 5.64
(5.66), N 2.98 (3.14).
'H NMR (CDC13): s 9.75 (dd, lH, J=2.3 Hz, J=1.0 Hz);
8.97 (dd, 1H, J=2.3, J=16.6 Hz); 8.93 (m, lH); 8.46
(ddd, 1H, J=1.3 Hz, J=7.1 Hz, J=15.9 Hz); 7.85 (ddd,
1H, J=3.6 Hz, J=7.1 Hz, J=8.4 Hz); 3.9-4.6 (m, 8H);
1.38 (t, 12H, J=7.2 Hz).
EI MS : 445 (M)+.
Example 12 3-Aminonaphthalene-l, 5-diphosphonic acid tetraethyl ester [Compound (III), R'= -PO(OEt)2, p= 2 ].
3-Nitronaphthalene-1, 5-diphosphonic acid tetraethyl ester of Example 11 (4.00 g, 9.0 mmol) dissolved in methanol
(150 ml) and 1N HC1 aqueous solution (10 ml) is stirred with H2 and 5% Pd/C in a PARR apparatus until H2 absorption ceased. After catalyst filtration on filter aid, the methanol is evaporated under reduced pressure; the residue is stirred with ethanol (10 ml) and diethyl ether (50 ml) and the separated crystalline solid is filtered, washed and dried to yield the title compound as the hydrochloride hemihydrate (3.78 g, decomp 230-240 C, 91% yield).
Cl8H28ClNO6P2.0.5H2O found (calc) % : C 46.99 (46.91), H
6.32 (6.34), N 3.02 (3.04).
1H NMR (CDCl3) : 6 8.3 (bs, lH); 9.03 (d, 1H, J=2.1 Hz);
8.77 (d, 1H, J=8.5 Hz); 8.50 (dd, 1H, J=2.1 Hz, J=16.6
Hz); 8.26 (ddd, lH, J=1.3 Hz, J=7.2 Hz, J=15.6 Hz);
7.65 (ddd, 1H, J=3.9 Hz, J=7.2 Hz, J=8.5 Hz); 3.9-4.5
(m, 8H); 1.3-1.5 (m, 12H).
Example 13 2-[(4-Nitro-1-methylpyrrole-2-carbonyl)amino]naphthalene- 4,8-diphosphonic acid tetraethyl ester [Compound (VIII),
R'= -PO(OEt) 2, p= 2, Z= NO2, E= -CH= ].
To an ice-cooled solution of 3-aminonaphthalene-1,5diphosphonic acid tetraethyl ester of Example 12 (3.75 g, 8.14 mmol, as hydrochloride hemihydrate) and triethylamine (3.75 ml, 27 mmol) in dichlorometane (60 ml, ethanol free) 4-nitro-1-methylpyrrole-2-carboxylic acid chloride (1.89 g, 10 mmol) dissolved in dichloromethane (15 ml) is added dropwise. After leaving 4 hrs at room temperature, the organic phase is washed with
H2O, 1N HCl followed by 5% NaHCO3 solution, dried (Na2SO4) and evaporated under reduced pressure to small volume and then purified by flash-chromatography on Silica Gel 60 (CH2Cl2 95-MeOH 5). The solid residue is taken up with diethyl ether, filtered and dried, to afford the title compound (4.17 g, m.p. 250.5-252.5 C, 90% yield).
C24H3,N3O9P2 found (calc.): C 50.87 (50.79), H 5.53
(5.51), N 7.35 (7.40).
1H NMR (CDCl3): 6 9.77 (s, lH); 9.23 (d, 1H, J=2.2);
8.65 (dd, 1H, J=1.4 Hz, J=8.4 Hz); 8.55 (dd, 1H, J=2.2
Hz, J= 17.4 Hz); 8.13 (ddd, 1H, J=1.4 Hz, J=7.3 Hz,
J=16.0 Hz); 7.3-7.7 (m, 3H); 3.9-4.5 (m, 8H); 3.87 (s,
3H); 1.1-1.6 (m, 12H).
EI MS : 567 (M)+.
Example 14 2-[(4-Amino-l-methylpyrrole-2-carbonyl)amino]naphthalene4,8-diphosphonic acid tetraethyl ester, hydrochloride compound (II), R'= -PO(OEt)2, p= 2, m= 1, E= -CH= ].
2-[(4-Nitro-1-methylpyrrole-2-carbonyl)amino]naphthalene4, 8-diphosphonic acid tetraethyl ester of Example 13
(4.45 g, 7.31 mmol) dissolved in methanol (150 ml) and 1N
HCl (7.5 ml) is hydrogenated in presence of 5% Pd/C in a
PARR apparatus until H2 absorption ceased. After catalyst filtration on filter aid, the methanol is evaporated under reduced pressure and the residue is dried in vacuum and passed to the acylation step without further purification.
'H NMR (CDCl3): 6 9.6 (s, lH); 9.05 (m, lH); 8.67 (dd, 1H, J=l.9 Hz, J=17.6 Hz); 8.67 (d, 1H, J=8.6 Hz); 8.12
(dd, 1H, J=6.5 Hz, J=15.9 Hz); 7.75 (s, 1H); 7.55 (m,
lH); 6.87 (s, 1H); 3.9-4.4 (m, 8H); 3.75 (s, 3H); 1.0
1.4 (m, 12H).
Example 15 2-({4-[ (4-Nitro-1-methylpyrrole-2-carbonyl)amino]-l- methylpyrrole-2-carbonyl}amino)naphthalene-4,8diphosphonic acid tetraethyl ester [Compound (V), R'= PO(OEt)2, p= 2, m= 2, Z= -NO2, E= -CH= ].
2-[(4-Amino-l-methylpyrrole-2-carbonyl)amino]naphthalene4, 8-diphosphonic acid tetraethyl ester of Example 14 (7.3 mmol as hydrochloride) and triethylamine (3.5 ml, 25 mmol) in dichloromethane (100 ml, ethanol free) are treated dropwise, with ice-bath cooling, with 4-nitro-lmethylpyrrole-2-carboxylic acid chloride (1.41 g, 7.5 mmol) dissolved in dichloromethane (15 ml). After leaving 1 h in ice and 1 h at room temperature, the organic phase is washed with acid and NaHCO3 solutions, dried (Na2SO4) and evaporated under reduced pressure. The crude residue redissolved in ethanol (20 ml) is scratched to induce crystal formation; crystallization is completed with diethyl ether (20 ml) and the separated crystalline yellow solid is filtered, washed with an ethanol-diethyl ether 1:1 mixture and dried at 50 C under reduced pressure to yield the title compound (4.50 g, m.p. 163168 C, 89 % yield).
C3Ji37N5O,0P2 found (calc.) % : N 9.85 (10.16).
(-)FAB MS : 688 (M-H)-.
H NMR (DMSO-d6): 6 10.34, 10.49 (two singlets, 2H);
9.23 (s, lH); 8.61 (d, 1H, J=8.4 Hz); 8.57 (dd, 1H, J=2.0 Hz, J=17.6 Hz); 8.12 (dd, 1H, J=7.0 Hz, J=16.1
Hz); 7.63 (ddd, 1H, J=4.2 Hz, J=7.0 Hz, J=8.4 Hz);
7.60, 8.19 (two doublets, 2H, J=1.8 Hz); 7.26, 7.37
(two doublets, J=1.8 Hz); 4.0-4.2 (m, 8H); 3.90, 3.96
(two singlets, 6H); 1.1-1.3 (m, 12H).
Example 16 2-({4-[(4-Amino-1-methylpyrrole-2-carbonyl)amino]-1- methylpyrrole-2-carbonyl}amino)naphthalene-4,8diphosphonic acid tetraethyl ester hydrochloride compound (II), R'= -PO(OEt)2, p = 2, m = 2, E = -CH= ].
2-({4-[(4-Nitro-1-methylpyrrole-2-carbonyl)amino]-1methylpyrrole-2-carbonyl}amino)naphthalene-4,8diphosphonic acid tetraethyl ester of Example 15 (4.50 g, 6.52 mmol) dissolved in methanol (350 ml) and aqueous 1N
HCl (7.0 ml) is hydrogenated with 5% Pd/C (500 mg) in a
PARR apparatus until H2 absorption ceased. After catalyst filtration, methanol is evaporated under reduced pressure. The residue is taken up in diethyl ether and the separated microcrystalline solid is filtered, washed and dried at 60 C under reduced pressure to give the title compound (4.43 g, 96% yield) as hydrochloride.
C30H40ClN5O8P2 found (calc.) % : C 49.93 (51.76), H 5.93
(5.79), Cl 5.00 (5.09), N 9.61 (10.06).
(-)FAB MS : 658 (M-H)-.
1H NMR (DMSO-d6): 6 10.13, 10.46 (two singlets, 2H);
9.85 (bs, 3H); 9.23 (s, lH); 8.60 (d, 1H, J=8.5 Hz);
8.56 (dd, 1H, J=2.0 Hz, J=17.3 Hz); 8.12 (dd, 1H, J=7.3
Hz, J=17.0 Hz); 7.64 (ddd, lH, J=3.5 Hz, J=7.3 Hz,
J=8.5 Hz); 7.26, 7.36 (two doublets, 2H, J=1.8 Hz);
7.00, 7.10 (two doublets, 2H, J=2.0 Hz); 4.0-4.2 (m,
8H); 3.89 (s, 6H); 1.2-1.3 (m, 12H).
Example 17 Carbonylbis-2-{[4-({4[ (3-amino-1-methylpyrazole-5- carbonyl)amino]-l-methylpyrrole-2-carbonyl}amino)-1- methylpyrrole-2-carbonyl]amino}naphthalene-4,8diphosphonic acid octaethyl ester [Compound (I), R' = O(OEt)2, p = 2 , m = 3, E = -N= and -CH= ].
A mixture of 2- ({4-[ (4-amino-l-methylpyrrole-2-carbonyl) amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene-4,8diphosphonic acid tetraethyl ester hydrochloride of
Example 16 (300 mg, 0.43 mmol) and 3-3'-carbonylbis-[5
(N-imidazolecarbonyl)-3-amino-1-methylpyrazole] of
Example 6 (82 mg, 0.20 mmol) in N,N-dimethylformamide (10 ml) is warmed under N2 at 40-50 C C for 2 hrs.
Dimethylformamide is distilled in vacuum; the residue, redissolved in dichloromethane, is washed with H20, 0.5N
HCl, NaHCO3 solution, dried and evaporated under reduced pressure. The crude residue is purified by flashchromatography on Silica-Gel 60 (CH2C12 85 - EtOH 15).The solid residue is taken up with ethyl acetate, filtered and dried to afford the title compound (160 mg, 50% yield) as a crystalline pale-brown solid.
'H NMR (DMSO-d6) : s 10.52, 10.48, 10.09 (three
singlets, 3H, exch. with DO); 9.4 (bs, lH, exch. with D2O); 9.25 (s, lH); 8.7-8.5 (m, 2H); 8.13 (dd, lH,
J=7.0 Hz, J=15.8 Hz); 7.64 (ddd, lH, J=3.7 Hz, J=7.0
Hz, J=7.6 Hz); 7.4-7.1 (m, 4H); 7.11 (s, lH); 4.3-3.9
(m, 8H); 4.01 (s, 3H); 3.90, 3.89 (two singlets, 6H);
1.4-1.1 (m, 12 H).
(+)FAB MS : 1591 (M+H)+, 1177, 783, 538.
(-)FAB MS : 1589 (M-H)-.
By proceeding analogously the alkyl and aryl-alkyl esters of the following compounds can be obtained: Carbonylbis-2-({3-[ (3-amino-1-methylpyrazole-5- carbonyl)amino]-1-methylpyrazole-5-carbonyl}amino) naphthalene-4 , 8-diphosphonic acid; Carbonylbis-2- ( {4-[ (3-amino-1-methylpyrazole-5-carbonyl) amino]-l-methylpyrrole-2-carbonyl}amino)naphthalene
4, 8-diphosphonic acid;
Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene- 4,8-diphosphonic acid; Carbonylbis-l- ({3-[ (3-amino-l-methylpyrazole-5-carbonyl)
amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene- 4,6-diphosphonic acid; Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-l-methylpyrrole-2-carbonyl}amino)naphthalene
4,6-diphosphonic acid; Carbonylbis-l-({3-t(4-amino-l-methylpyrrole-2-carbonyl)
amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene- 4,6-diphosphonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene- 6,8-diphosphonic acid; Carbonylbis-l-({3-t(4-amino-1-methylpyrrole-2-carbonyl) amino]-l-methylpyrazole-5-carbonyl}amino)naphthalene
5,7-diphosphonic acid;
Carbonylbis-1-{[4-({4-[(3-amino-1-methylpyrazole-5 carbonyl)amino]-1-methylpyrrole-2-carbonyl}amino)-1-
methylpyrrole-2-carbonyl]amino}naphthalene-4,6- diphosphonic acid;
Carbonylbis-2-{[4-({4-[(5-amino-1-methylpyrazole-3 carbonyl)amino]-1-methylpyrrole-2-carbonyl}amino) -1- methylpyrrole-2-carbonyl]amino}naphthalene-4,8 diphosphonic acid; Carbonylbis-l-({4-[ (3-amino-l-methylpyrazole-5- carbonyl)
amino]-l-methylpyrrole-2-carbonyl}amino)naphthalene
6,8-diphosphonic acid; and Carbonylbis-l-({4-[ (3-amino-l-methylpyrazole-5- carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
5,7-diphosphonic acid.
Example 18 Carbonylbis-2-{ [4-({4-[ (3-amino-l-methylpyrazole-5- carbonyl)amino]-l-methylpyrrole-2-carbonyl}amino)-1 methylpyrrole-2-carbonyl]amino}naphthalene-4,8- diphosphonic acid and tetrasodium salt [Compound (I), R' = -PO(OH)2, p= 2, m = 3, E = -N= and -CH= ).
To an ice-cooled solution of the octaethyl ester compound obtained in Example 17 (135 mg, 0.085 mmol) in dry dichloromethane (20 ml), bromotrimethylsilane (0.8 ml) is added dropwise with stirring . After leaving 48 hrs at room-temperature, the organic volatiles are evaporated under reduced pressure. The residue is taken up with acetone (10 ml) and H2O (100 mg) is added. After stirring for 4 hrs, the separated microcrystalline yellow solid is filtered, washed with acetone and vacuum dried to give the title acid (115 mg, near quantitative yield).
'H NMR (DMSO-d6): 6 10.52, 10.35, 10.06 (three singlets,
3H, exch. with D2O); 9.3 (bs, 1H, exch. with D2O); 9.10
(s, lH); 8.68 (d, 1H, J=8.7 Hz); 8.48 (dd, 1H, J=2.1
Hz, J=17.1 Hz); 8.05 (ddd, 1H, J=l.1 Hz, J=6.2 Hz,
J=15.1 Hz); 7.53 (m, lH); 7.4-7.1 (m, 4H); 7.10 (s,
lH); 4.02 (s, 3H); 3.89 (s, 6H).
The acid thus obtained (115 mg, 0.084 mmol) is suspended in H2O (10 ml) and neutralized with 0.1N NaOH to pH 5.56.0. The solution thus obtained is filtered, concentrated under reduced pressure to small volume and freeze-dried to microcrystalline pale-yellow title tetrasodium salt (145 mg, air equilibrated).
By analogous procedures, the following compounds can be obtained either as free or sodium salified acids:
Carbonylbis-2-({3-[(3-amino-1-methylpyrazole-5
carbonyl)amino]-1-methylpyrazole-5-carbonyl}amino) naphthalene-4 , 8-diphosphonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl) amino)-l-methylpyrrole-2-carbonyl}amino) naphthalene- 4,8-diphosphonic acid;
Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino)-l-methylpyrazole-5-carbonyl}a'nino) naphthalene- 4, 8-diphosphonic acid; Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl)
amino) -l-methylpyrazole-5-carbonyl}amino) naphthalene- 4,6-diphosphonic acid; Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino)-l-methylpyrrole-2-carbonyl}a'nino) naphthalene- 4,6-diphosphonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino) -l-methylpyrazole-5-carbonyl } amino) naphthalene- 4,6-diphosphonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino] -l-methylpyrazole-5-carbonyl}amino) naphthalene- 6, 8-diphosphonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl)
amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene
5,7-diphosphonic acid;
Carbonylbis-1-{[4-({4-[(3-amino-1-methylpyrazole-5 carbonyl) ainino)-l-methylpyrrole-2-carbonyl}amino) -1-
methylpyrrole-2-carbonyl]amino}naphthalene-4,6- diphosphonic acid;
Carbonylbis-2-{[4-({4-[(5-amino-1-methylpyrazole-3
carbonyl)amino]-1-methylpyrrole-2-carbonyl}amino)-1
methylpyrrole-2-carbonyl]amino}naphthalene-4,8
diphosphonic acid; Carbonylbis-l-({4-[(3-amino-l-methylpyrazole-S-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene- 6,8-diphosphonic acid; and Carbonylbis-l- ( {4-[ (3-amino-l-methylpyrazole-5-carbonyl) amino]-l-methylpyrrole-2-carbonyl}amino)naphthalene
5,7-diphosphonic acid.
Example 19
Intramuscular injection 40 mg/ml.
An injectable pharmaceutical preparation can be manufactured by dissolving 40 g of Carbonylbis-2-({3-[ (3- amino-1-methylpyrazole-5-carbonyl)amino]-1-methyl pyrazole-5-carbonyl}amino)naphthalene-6,8-disulfonic acid tetrapotassium salt in water for injection (1000 ml) and sealing ampoules of 1-10 ml.
Example 20
Capsules, each dosed at 0.200 g and containing 20 mg of the active substance can be prepared.
Composition for 500 capsules: Carbonylbis-2- ( {3-[ (3-amino-l-methylpyrazole-5-carbonyl) amino]-l-methyl pyrazole-5-carbonyl)amino)naphthalene- 6,8-disulfonic acid tetrapotassium salt 10 g
Lactose 80 g
Corn starch 5 g
Magnesium stearate sg This formulation is encapsulated in two-piece hard gelatin capsules and dosed at 0.200 g for each capsule.
Claims (14)
1. A compound of formula (I)
B-CO-B (I)
wherein each of the B groups, which are the same, is
a group (i)
wherein
m is an integer of 1 to 6;
p is an integer of 1 to 3;
E is a group -CH= or -N=;
each of the R groups, which are the same, is a free
or esterified acid group; and the pharmaceutically
acceptable salts thereof;
and wherein when m is 1, then E is -N=; whereas when
m is an integer of 2 to 6, then at least one of the
E groups is -N=.
2. A compound of formula (I) as defined in claim 1,
wherein each of the B groups, which are the same, is
a group (i), as defined in claim 1, wherein m is 2 or 3;
one of the E groups is -N=, the others being -N= or
-CH=; p is 2 or 3; and each of the R groups, which
are the same, is a free or esterified phosphonic or
sulfonic acid group; and the pharmaceutically
acceptable salts thereof.
3. An ester of a compound of formula (I) as defined in
claims 1 or 2, wherein said ester is a C-C6 alkyl
ester or a phenyl-C,-C6 alkyl ester.
4. A compound selected from the group consisting of:
Carbonylbis-2-({3-[(3amino-1-methylpyrazole-5-carbonyl) amino] -l-methylpyrazole-5-carbonyl )amino) naphthalene- 6,8-disulfonic acid; Carbonylbis-2- ( {4-[ (3-amino-l-methylpyrazole-5-carbonyl) amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
6,8-disulfonic acid;
Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl)
amino]-l-methylpyrazole-5-carbonyl}amino)naphthalene
6,8-disulfonic acid; Carbonylbis-2-({5-[(5-amino-1-methylpyrazole-3-carbonyl)
amino] -l-methylpyrazole-3-carbonyl}amino) naphthalene- 6,8-disulfonic acid; carbonylbis-2-({4-[(5-amino-l-methylpyrazole-3-carbonyl) amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
6,8-disulfonic acid;
Carbonylbis-2-({5-[(4-amino-1-methylpyrrole-2-carbonyl)
amino] -l-methylpyrazole-3-carbonyl}amino) naphthalene
6,8-disulfonic acid;
Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino) -l-methylpyrazole-5-carbonyl}amino) naphthalene- 4,6,8-trisulfonic acid; Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino] -l-methylpyrrole-2-carbonyl}ainino) naphthalene- 4,6,8-trisulfonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino] -l-methylpyrazole-5-carbonyl }amino) naphthalene- 4,6,8-trisulfonic acid; Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene- 4,6-disulfonic acid;
Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
4,6-disulfonic acid; Carbonylbis-l- ( {3-[ (4-amino-1-methylpyrrole-2-carbonyl)
amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene- 4,6-disulfonic acid;
Carbonylbis-2-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino ] -l-methylpyrazole-5-carbonyl )amino) naphtha lene- 4,6,8-trisulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-l-methylpyrrole-2-carbonyl}amino)naphthalene 4, 6, 8-trisulfonic acid;
Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl)
amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene
4,6,8-trisulfonic acid;
Carbonylbis-2-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino] -l-methylpyrazole-5-carbonyl )amino) naphthalene- 1,5-disulfonic acid; Carbonylbis-2- ({4- (3-amino-1-methylpyrazole-5-carbonyl) amino]-l-methylpyrrole-2-carbonyl}amino)naphthalene
1,5-disulfonic acid;
Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino] -l-methylpyrazole-5-carbonyl} amino) naphthalene- 1,5-disulfonic acid; Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene
8-sulfonic acid;
Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
8-sulfonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino ] -l-methylpyra zole-5-carbonyl )amino) naphtha lene- 8-sulfonic acid;
Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino) -l-methylpyrazole-5-carbonyl } amino) naphthalene- 4-sulfonic acid;
Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
4-sulfonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino] -l-inethylpyrazole-5-carbonyl}amino) naphthalene- 4-sulfonic acid;
Carbonylbis-2-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-1-methylpyrazole-5-carbonyl}amino)-5-hydroxy naphthalene-7-sulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)-5-hydroxy
naphthalene-7-sulfonic acid; Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino]-1-methylpyrazole-5-carbonyl}amino)-5-hydroxy
naphthalene-7-sulfonic acid; Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
4,6-disulfonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene- 5,7-disulfonic acid;
Carbonylbis-1-{[4-({4-[(3-amino-1-methylpyrazole-5 carbonyl) -amino] -l-methylpyrrole-2-carbonyl}amino) -1- methyl-pyrrole-2-carbonyl]amino}naphthalene-4,6
disulfonic acid;
Carbonylbis-2-{[4-({4-[(3-amino-1-methylpyrazole-5 carbonyl) -amino] -l-methylpyrrole-2-carbonyl}amino) -1- methyl-pyrrole-2-carbonyl]amino)naphthalene-4,6,8
trisulfonic acid;
Carbonylbis-2-{[3-({4-[(4-amino-1-methylpyrrole-2 carbonyl)-amino]-1-methylpyrrole-2-carbonyl}amino)-1-
methyl-pyrazole-5-carbonyl]amino}naphthalene-4/6/8- trisulfonic acid;
Carbonylbis-2-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino] -l-methylpyrazole-5-carbonyl }amino) naphthalene- 4,8-diphosphonic acid;
Carbonylbis-2-({4-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene- 4,8-diphosphonic acid;
Carbonylbis-2-({3-[(4-amino-1-methylpyrrole-2-carbonyl)
amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene
4,8-disphosphonic acid;
Carbonylbis-1-({3-[(3-amino-1-methylpyrazole-5-carbonyl) amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene- 4,6-disphosphonic acid; Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl) aimino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
4,6-diphosphonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl)
amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene
4,6-disphosphonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino]-1-methylpyrazole-5-carbonyl}amino)naphthalene- 6,8-diphosphonic acid;
Carbonylbis-1-({3-[(4-amino-1-methylpyrrole-2-carbonyl) amino] -l-methylpyrazole-5-carbony I)amino) naphthalene- 5,7-disphosphonic acid; Carbonylbis-2-{[4-({4-[ (3-amino-1-methylpyrazole-5-
carbonyl)amino]-1-methylpyrrole-2-carbonyl}amino)-1- methylpyrrole-2-carbonyl]amino}naphthalene-4,8
diphosphonic acid;
Carbonylbis-1-{[4-({4-[(3-amino-1-methylpyrazole-5
carbonyl)amino]-1-methylpyrrole-2-carbonyl}amino)-1 methylpyrrole-2-carbonyl] amino}naphthalene-4 , 6- diphosphonic acid;
Carbonylbis-2-{[4-({4-[(5-amino-1-methylpyrazole-3
carbonyl)amino]-1-methylpyrrole-2-carbonyl}amino)-1 methylpyrrole-2-carbonyl] amino}naphthalene-4 , 8- diphosphonic acid;
Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
6,8-disphosphonic acid;
Carbonylbis-1-({4-[(3-amino-1-methylpyrazole-5-carbonyl)
amino]-1-methylpyrrole-2-carbonyl}amino)naphthalene
5,7-disphosphonic acid; and the C-C6-alkyl and phenyl-C-C6-alkyl esters and the pharmaceutically acceptable salts thereof.
5. A process for the preparation of a compound of
formula (I), as defined in claim 1, or a salt
thereof, the process comprising reacting a compound
of formula (II) or (III), respectively
wherein m, p, E and R are as defined in claim 1, or a salt thereof, with a compound of formula (IV)
wherein each of the X groups, which may be the same or different, is a good leaving group, E is as defined in claim 1, q is 0 to 6 and wherein, when a compound of formula (IV) is reacted with a compound of formula (II), then q is 0 to 5 in such a way that [q+(m-l)] is 0 to 5, whereas when a compound of formula (IV) is reacted with a compound of formula (III), then q is an integer of 1 to 6 and, if desired, converting a compound of formula (I) into another compound of formula (I), and/or, if desired, salifying a compound of formula (I) thus obtained, and/or, if desired,
obtaining a free acid of formula (I) from an ester or
a salt thereof, and/or, if desired, esterifying an
acid of formula (I).
6. A pharmaceutical composition comprising a pharma
ceutically acceptable carrier and/or diluent and, as
an active principle, a compound of formula (I), as
defined in claim 1, or a pharmaceutically acceptable
salt thereof.
7. A compound of formula (I), as defined in claim 1, or
a pharmaceutically acceptable salt thereof, for use
as a medicament.
8. A compound of formula (I), as defined in claim 1, or
a pharmaceutically acceptable salt thereof, for use
as anti-lentivirus agent.
9. A compound of formula (I), as defined in claim 1, for
use as an angiogenesis inhibitor.
10. A compound of formula (I), as defined in claim 1, for
prophylactic and/or therapeutic use in a disease
state in which TNFa plays a detrimental role.
11. A compound of formula (I), as defined in claim 1, or
a pharmaceutically acceptable salt thereof, for use
in ameliorating the symptoms manifested by a human
patient who is seropositive diseased, stressed or
pathological as a result of infection with a
lentivirus or who is suffering from lentivirus
induced disease.
12. Products containing a compound of formula (I) or a
pharmaceutically acceptable salt thereof, as defined
in claim 1, and a second active agent as a combined
preparation for simultaneous, separate or sequential
use in the treatment of a human patient suffering
from lentivirus infection.
13. A compound of formula (II) or a salt thereof
wherein m, p, E and R are as defined in claim 1.
14. A compound of formula (III)
wherein p is as defined in claim 1 and R is a free, salified or esterified phosphonic acid group.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9603213A GB2310207A (en) | 1996-02-15 | 1996-02-15 | Antiviral ureido derivatives of substituted heterocyclic compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9603213A GB2310207A (en) | 1996-02-15 | 1996-02-15 | Antiviral ureido derivatives of substituted heterocyclic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
GB9603213D0 GB9603213D0 (en) | 1996-04-17 |
GB2310207A true GB2310207A (en) | 1997-08-20 |
Family
ID=10788826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB9603213A Withdrawn GB2310207A (en) | 1996-02-15 | 1996-02-15 | Antiviral ureido derivatives of substituted heterocyclic compounds |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2310207A (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999000364A1 (en) * | 1997-06-27 | 1999-01-07 | Pharmacia & Upjohn S.P.A. | Poly-branched polycarboxamido compounds |
WO1999027939A1 (en) * | 1997-12-04 | 1999-06-10 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds for inhibition of inflammation |
WO2001074898A2 (en) * | 2000-03-16 | 2001-10-11 | Genesoft, Inc. | Charged compounds comprising a nucleic acid binding moiety and uses therefor |
WO2003018552A2 (en) * | 2001-08-30 | 2003-03-06 | Pharmacia Corporation | Aromatic and heteroaromatic acid halides for synthesizing polyamides |
US6750230B2 (en) | 2000-07-07 | 2004-06-15 | Pfizer, Inc. | Pyrazole derivatives |
WO2004099155A2 (en) * | 2003-05-02 | 2004-11-18 | Elan Pharmaceuticals, Inc. | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivates and related compounds as bradykinin b1 receptor antagonists for the treatment of inflamatory diseases |
WO2005094805A1 (en) * | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | Imine derivative and amide derivative |
US7078536B2 (en) | 2001-03-14 | 2006-07-18 | Genesoft Pharmaceuticals, Inc. | Charged compounds comprising a nucleic acid binding moiety and uses therefor |
US7129214B2 (en) | 2002-12-10 | 2006-10-31 | Oscient Pharmaceuticals Corporation | Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif |
US7265129B2 (en) | 2002-10-25 | 2007-09-04 | Genesoft Pharmaceuticals, Inc. | Anti-infective biaryl compounds |
US7417152B2 (en) | 2003-05-02 | 2008-08-26 | Elan Pharmaceuticals, Inc. | 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases |
US7498349B2 (en) | 2002-08-02 | 2009-03-03 | Genesoft Pharmaceuticals, Inc. | Biaryl compounds having anti-infective activity |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991010649A1 (en) * | 1990-01-11 | 1991-07-25 | Farmitalia Carlo Erba S.R.L. | New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
GB2260134A (en) * | 1991-10-04 | 1993-04-07 | Erba Carlo Spa | Derivatives of poly-5-amino-3-carboxy-1-methyl compounds |
WO1994023718A1 (en) * | 1993-04-16 | 1994-10-27 | Farmitalia Carlo Erba S.R.L. | Biologically active ureido derivatives useful in the treatment of lentivirus-induced disease |
WO1995023806A2 (en) * | 1994-03-01 | 1995-09-08 | Pharmacia S.P.A. | Ureido derivatives of naphthalenephosphonic acids and process for their preparation |
-
1996
- 1996-02-15 GB GB9603213A patent/GB2310207A/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991010649A1 (en) * | 1990-01-11 | 1991-07-25 | Farmitalia Carlo Erba S.R.L. | New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
GB2260134A (en) * | 1991-10-04 | 1993-04-07 | Erba Carlo Spa | Derivatives of poly-5-amino-3-carboxy-1-methyl compounds |
WO1994023718A1 (en) * | 1993-04-16 | 1994-10-27 | Farmitalia Carlo Erba S.R.L. | Biologically active ureido derivatives useful in the treatment of lentivirus-induced disease |
WO1995023806A2 (en) * | 1994-03-01 | 1995-09-08 | Pharmacia S.P.A. | Ureido derivatives of naphthalenephosphonic acids and process for their preparation |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999000364A1 (en) * | 1997-06-27 | 1999-01-07 | Pharmacia & Upjohn S.P.A. | Poly-branched polycarboxamido compounds |
US6562859B1 (en) | 1997-12-04 | 2003-05-13 | The United States Of America As Represented By The Department Of Health And Human Services | Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds for inhibition of inflammation |
WO1999027939A1 (en) * | 1997-12-04 | 1999-06-10 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds for inhibition of inflammation |
WO2001074898A3 (en) * | 2000-03-16 | 2003-01-16 | Genesoft Inc | Charged compounds comprising a nucleic acid binding moiety and uses therefor |
US6555693B2 (en) | 2000-03-16 | 2003-04-29 | Genesoft, Inc. | Charged compounds comprising a nucleic acid binding moiety and uses therefor |
US7301037B2 (en) | 2000-03-16 | 2007-11-27 | Genesoft, Inc. | Charged compounds comprising a nucleic acid binding moiety and uses therefor |
WO2001074898A2 (en) * | 2000-03-16 | 2001-10-11 | Genesoft, Inc. | Charged compounds comprising a nucleic acid binding moiety and uses therefor |
US7141585B2 (en) | 2000-07-07 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
US6750230B2 (en) | 2000-07-07 | 2004-06-15 | Pfizer, Inc. | Pyrazole derivatives |
US7078536B2 (en) | 2001-03-14 | 2006-07-18 | Genesoft Pharmaceuticals, Inc. | Charged compounds comprising a nucleic acid binding moiety and uses therefor |
WO2003018552A2 (en) * | 2001-08-30 | 2003-03-06 | Pharmacia Corporation | Aromatic and heteroaromatic acid halides for synthesizing polyamides |
WO2003018552A3 (en) * | 2001-08-30 | 2003-05-30 | Pharmacia Corp | Aromatic and heteroaromatic acid halides for synthesizing polyamides |
US6677487B2 (en) | 2001-08-30 | 2004-01-13 | Pharmacia Corporation | α-haloenamine reagents |
US6924396B2 (en) | 2001-08-30 | 2005-08-02 | Pharmacia Corporation | α-haloenamine reagents |
US7498349B2 (en) | 2002-08-02 | 2009-03-03 | Genesoft Pharmaceuticals, Inc. | Biaryl compounds having anti-infective activity |
US7265129B2 (en) | 2002-10-25 | 2007-09-04 | Genesoft Pharmaceuticals, Inc. | Anti-infective biaryl compounds |
US7129214B2 (en) | 2002-12-10 | 2006-10-31 | Oscient Pharmaceuticals Corporation | Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif |
US7642245B2 (en) | 2002-12-10 | 2010-01-05 | Oscient Pharmaceuticals Corporation | Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif |
JP2006525361A (en) * | 2003-05-02 | 2006-11-09 | エラン ファーマシューティカルズ,インコーポレイテッド | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists |
WO2004099155A3 (en) * | 2003-05-02 | 2005-11-10 | Elan Pharm Inc | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivates and related compounds as bradykinin b1 receptor antagonists for the treatment of inflamatory diseases |
US7417152B2 (en) | 2003-05-02 | 2008-08-26 | Elan Pharmaceuticals, Inc. | 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases |
US7432379B2 (en) | 2003-05-02 | 2008-10-07 | Elan Pharmaceuticals, Inc. | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists |
WO2004099155A2 (en) * | 2003-05-02 | 2004-11-18 | Elan Pharmaceuticals, Inc. | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivates and related compounds as bradykinin b1 receptor antagonists for the treatment of inflamatory diseases |
WO2005094805A1 (en) * | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | Imine derivative and amide derivative |
Also Published As
Publication number | Publication date |
---|---|
GB9603213D0 (en) | 1996-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5700788A (en) | Ureido derivatives of naphthalenephosphonic acids | |
US5420296A (en) | Ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds | |
JP4171702B2 (en) | Novel α-amino-N- (diaminophosphinyl) lactam derivative | |
KR20170098904A (en) | Necrosis inhibitor | |
JP2002528495A (en) | Nitrosated and nitrosylated non-steroidal anti-inflammatory compounds, compositions and methods of use | |
GB2310207A (en) | Antiviral ureido derivatives of substituted heterocyclic compounds | |
KR100681632B1 (en) | Phosphonic acid derivatives having carboxypeptidase B inhibitory activity | |
US5656617A (en) | Derivatives of purine, process for their preparation and a pharmaceutical preparation | |
HUT68936A (en) | Process for preparing 2-amino-1,2,3,4-tetrahydronaphtalene derivatives and pharmaceutical compositions containing them | |
TW202029965A (en) | Novel aminophosphinic derivatives as aminopeptidase a inhibitors | |
KR20010033069A (en) | Novel metalloproteinase inhibitors | |
WO1999000364A1 (en) | Poly-branched polycarboxamido compounds | |
JPH06184098A (en) | Therapeutically effective naphthalene sulfone pyrrole- carboxamide derivative | |
JP2023529047A (en) | Agent for use in treating tissue damage | |
EP2062884A1 (en) | Novel phenylacetic acid derivative | |
US5356922A (en) | Imidazole compounds, processes for their preparation, pharmaceuticals based on these compounds and some intermediates | |
WO1999000363A1 (en) | Substituted triazine compounds and their use in medicine | |
KR100483869B1 (en) | New Amino Acid Derivatives and Their Use as Thrombin Inhibitors | |
JP2001031637A (en) | New hydroxamic acid derivative | |
MXPA05006032A (en) | Crystalline derivative of 2- (5- chlorothien -2-yl) -n- ((3s) -1((1s)- 1-methyl -2- morpholin -4-yl) -2- oxoethyl) -2-oxopyrrolidin -3-yl) ethensulfonamide. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |